OpenAlex
PricingAboutJobs
Log inGet started
Work

Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial

HTML

Year: 2005
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The American Journal of Gastroenterology
DOI: 10.1111/j.1572-0241.2005.00248.x
Authors: Stephen B. Hanauer, William J. Sandborn, Asher Kornbluth, Seymour Katz, Michael Safdi, Scott Woogen, Gino Regalli, Chyon Yeh, Nancy Smith-Hall, Funmilay Ajayi
Institutions: University of Chicago Medical Center, Mayo Clinic, Icahn School of Medicine at Mount Sinai, Clinical Research Associates, Greater Pittsburgh Orthopaedic Associates, Procter & Gamble (United States)
Language: English

Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: ulcerative colitis, 5-aminosalicylic acid, dose comparison, treatment success, remission, clinical response, drug efficacy, tolerability
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2056461886
FWCI: 17.82
Cites: 16
Cited by: 338
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms